Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

17 results about "Urothelium" patented technology

Urothelium is an example of "transitional epithelium". It is the type of epithelium that lines much of the urinary tract including the renal pelvis, the ureters, the bladder, and parts of the urethra.

Antibody-drug conjugate and preparation method and use thereof

Provided are an antibody-drug conjugate and a preparation method and a use thereof, which has a structure shown in the formula Ab-[M-L-E-D] x, the drug is selected from DNA topoisomerase inhibitors, the prepared antibody-drug conjugate has a relatively good drug-antibody conjugation ratio and has excellent targeted killing effects on solid tumors such as gastric cancer, breast cancer, lung cancer, and urothelium carcinoma.
Owner:SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

Antibody-drug conjugate and preparation method and use thereof

Provided are an antibody-drug conjugate and a preparation method and a use thereof, which has a structure shown in the formula Ab-[M-L-E-D] x, the drug is selected from DNA topoisomerase inhibitors, the prepared antibody-drug conjugate has a relatively good drug-antibody conjugation ratio and has excellent targeted killing effects on solid tumors such as gastric cancer, breast cancer, lung cancer, and urothelium carcinoma.
Owner:SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

Polymethylated urothelial carcinoma early screening system and model construction method

The invention relates to the technical field of gene detection, in particular to a polymethylated urothelial carcinoma early screening system and a model construction method.The polymethylated urothelial carcinoma early screening system comprises an acquisition module for acquiring a to-be-screened tissue specimen and a para-carcinoma specimen; the gene screening module is used for carrying out RRBS comparison sequencing on the specimens obtained by the obtaining module and screening out specific marker genes with high specificity and high methylation level; the gene verification module is used for verifying the primarily screened marker gene through a BSP sequencing / MSP amplification technology; the urothelium carcinoma screening module is used for automatically outputting a screening result by constructing a polygene methylation detection kit and combining with a statistical model so as to realize urothelium carcinoma screening; through multi-gene methylation combined detection and in combination with a specific algorithm model, the sensitivity and the specificity are further improved, and the defects that the sensitivity of a single gene marker is low and the specificity is low after a plurality of gene markers are combined are overcome.
Owner:ANLONG GENE TECH CO LTD

Pharmaceutical composition comprising CDK inhibitor and id2 activator for prevention or treatment of bladder cancer

The present invention relates to a pharmaceutical composition including a CDK inhibitor and an ID2 activator for the prevention or treatment of bladder cancer, wherein based on the finding that: among CDK1-TFCP2L1 pathway targets associated with urothelial differentiation in bladder cancer cells, ID2 is a factor significantly correlating with the tumor grade of bladder cancer; an ID2 activator exhibits a therapeutic effect on bladder cancer; and the combined administration of CDK1 inhibitor and ID2 activator induces apoptosis of bladder cancer cells and significantly suppresses the invasiveness of cancer cells, compared to administration thereof alone, thereby exhibiting a therapeutic effect of remarkably suppressing the size and progression of bladder cancer, a composition comprising a CDK inhibitor and an ID2 activator and a method for combined administration thereof are provided as novel therapeutic means for the prevention or treatment of bladder cancer.
Owner:THE ASAN FOUND +1

Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders

The present invention provides methods, compositions, and kits for treating bladder disorders or conditions, in which botulinum toxin is topically administered to the mucosal inner lining or urothelium of the bladder, of a subject in need thereof, for transmucosal delivery across the urothelium to surrounding bladder wall musculature and / or neuronal tissue. Rather than requiring injection, the toxin instead may be administered by instillation in solution via the urethra. In particular, the botulinum toxin is administered in conjunction with a positively charged or lipophilic carrier comprising a positively charged polymeric backbone or a hydrophobic backbone with covalently attached groups that enhance transmucosal transport across the urothelium and may also stabilize the botulinum toxin in aqueous formulations.
Owner:REVANCE THERAPEUTICS INC

Ureteral stent tube and preparation method thereof

The present application relates to the field of medical devices and discloses a ureteral stent and a preparation method thereof. The ureteral stent comprises a stent body and a nanofiber membrane. The stent body is woven into a 90-140ppi tube by spinning component A and component B in a mass ratio of 4:(1-2). The spun yarn obtained by component B is melted by heating and then combined with the spun yarn obtained by component A. The stent body is obtained after cooling. The nanofiber membrane components include polyethylene glycol and polyglycolide, as well as fucoidan-modified chitosan. A lubricant is sprayed on one side of the nanofiber membrane away from the stent body, and the membrane is wound around the outer surface of the stent body by electrostatic adsorption. The ureteral stent increases the stability and stiffness of the tube wall, improves the mechanical strength and durability, and the material is biocompatible and biodegradable, and can reduce irritation and damage to the urothelium, and prevent urothelial tissue ingrowth and adhesion.
Owner:DONGHUA UNIV

Tubular porous scaffold integrated with amnion as well as preparation method and application of tubular porous scaffold

The invention provides an amnion-integrated tubular porous scaffold as well as a preparation method and application thereof. The preparation method comprises the following steps: (S10) extracting silk fibroin from silkworm cocoons by adopting a lithium bromide dissolution method; (S20) adopting detergent treatment and enzyme digestion to prepare the decellularized amnion; (S30) mixing silk fibroin and pigskin gelatin to prepare a silk fibroin / gelatin solution; and (S40) integrating the decellularized amniotic membrane with the silk fibroin / gelatin stent to obtain the tubular porous stent integrated with the amniotic membrane, so that the tubular porous stent can increase urinary tract epithelization and inhibit fibrosis, is suitable for being applied to ureter scar-free repair treatment, ureter defect repair treatment or ureter reconstruction, and provides a new treatment strategy for ureter defect repair treatment.
Owner:NINGBO FIRST HOSPITAL

Nucleic acid combination product for detecting bladder cancer or urothelium cancer and application of nucleic acid combination product

The invention relates to the technical field of biomedicine, in particular to a nucleic acid combination product for detecting bladder cancer or urothelial carcinoma and application of the nucleic acid combination product. According to the nucleic acid combination product, on the basis of detecting the primer pair and the probe of the single TWIST1 gene, the primer pair and the probe for detecting at least one of the two auxiliary genes NID2 and PENK are added, the positive detection rate and accuracy of bladder cancer and urothelial carcinoma are improved, and more possibilities are provided for early discovery and treatment of tumor diseases.
Owner:INTELLINOSIS BIOTECHNOLOGY (SHANGHAI) CO LTD

PUCP typing method based on MTRNR2L12 expression characteristics and application thereof

The invention relates to the technical field of tumor molecular diagnosis, and particularly discloses a primary prostate urothelium carcinoma (PUCP) typing method based on MTRNR2L12 expression characteristics and application of the primary prostate urothelium carcinoma (PUCP) typing method. The specific expression characteristics of the MTRNR2L12 gene in the primary prostatic urothelial carcinoma are systematically revealed from a plurality of links such as single cell separation and sequencing, data preprocessing and clustering, subtype division and CNV analysis, function enrichment analysis, public data integration and trajectory reconstruction, differential expression and clinical sample verification; therefore, the MTRNR2L12 can be used as a molecular marker for diagnosing the PUCP, and the accuracy of clinical early recognition is improved. The invention can be applied to molecular typing and auxiliary diagnosis of suspected prostate tumor samples, and has important clinical transformation potential.
Owner:SHANGHAI PUDONG HOSPITAL

Immune cell chemical detection kit for identifying urothelium tumor and staining method thereof

PendingCN119510757APreparing sample for investigationImmunoassaysNeutral buffered formalinEpithelium
The invention relates to an immune cell chemical detection kit for identifying urinary tract epithelial tumors and a dyeing method thereof, and belongs to the field of immune detection. The kit comprises 10% neutral buffer formalin, a nuclear primary antibody, a cytoplasm primary antibody, an HRP-labeled secondary antibody polymer, an AP-labeled secondary antibody polymer, a DAB staining solution and a basic fuchsin staining solution. The cell nucleus primary antibody is selected from p53 or Ki67, and the cytoplasm primary antibody is selected from CK17 or CK20. According to the method, urine exfoliated cells are subjected to liquid-based slide making and combined with an immunochemical double staining method to identify the urinary tract epithelium tumor related antigen, and during immunochemical double staining, a 10% neutral buffer formalin short-time fixation and antigen low-temperature repair method is utilized, so that the integrity of the cells is ensured, the identification time is greatly saved, and the identification efficiency is improved. In addition, the antigen is fully exposed, clearer positive cells are obtained, the dyeing quality is ensured, and the identification accuracy of the urothelium tumor associated antigen is improved.
Owner:HENAN CELNOVTE BIOTECHNOLOGY CO LTD

Ureteral stent tube and preparation method thereof

The invention relates to the field of medical instruments, and discloses a ureteral stent tube and a preparation method thereof.The ureteral stent tube comprises a stent tube body and a nanofiber membrane, the stent tube body is formed by blending and weaving a component A and a component B according to the mass ratio of 4: (1-2) into a 90-140 ppi tubular shape, the preparation method comprises the following steps: preparing a component A from a nanofiber membrane, heating to melt the spinning obtained from the component B, combining with the spinning obtained from the component A, and cooling to obtain a stent tube body, the nanofiber membrane comprises polyethylene glycol, polyglycolide and fucoidin modified chitosan, one side of the nanofiber membrane deviating from the stent tube body is sprayed with a lubricant, and the other side of the nanofiber membrane deviating from the stent tube body is sprayed with an antioxidant. According to the ureter stent tube, the stability and rigidity of the tube wall are improved, the mechanical strength and durability are improved, the material has biocompatibility and biodegradability, stimulation and damage to urinary tract epithelium can be reduced, and urinary tract epithelium tissue ingrowth and urinary tract epithelium tissue adhesion are prevented.
Owner:DONGHUA UNIV

Urothelium carcinoma methylation marker kit

The invention relates to a methylation marker kit for urinary tract epithelial cancer, and further relates to a reagent capable of detecting the methylation state of a DNA area where a target gene in a sample is located and application of the reagent in preparation of the urinary tract epithelial cancer detection kit, and the target gene comprises HOXA9 and / or any one or more genes selected from the group consisting of VIM, SIM2, ZIC4, ZNF154, KCNMA1, FOXF2, TRPS1, RAB37, SEPT9, LHX8, NKX6-2, ZNF571-AS1, NKX1-1, MARCH11, PENK, TBX15, NKX2-8, NRN1, BCL11B, ALX1, KCNQ1DN, LRRC9, BNC1, IRX4 The invention also provides a method for detecting urothelial carcinoma.
Owner:ACORNMED BIOTECHNOLOGY CO LTD BEIJING +2

TGF-beta1 signal channel inhibitor, method for regulating expression of Fmod by using TGF-beta1 signal channel inhibitor and application of TGF-beta1 signal

The invention provides a TGF-beta1 signal channel inhibitor and a method and application thereof for regulating and controlling Fmod expression, the TGF-beta1 signal channel inhibitor is decellularized amnion integrated silk fibroin / gelatin, TGF-beta1 signal transduction is antagonized by up-regulating Fmod expression, the TGF-beta1 signal channel inhibitor is suitable for being applied to a ureter porous stent, urinary tract epithelization can be increased, fibrosis can be inhibited, and the TGF-beta1 signal channel inhibitor can be used for preparing a ureter stent. Therefore, the method is used for ureteral scar-free repair treatment, ureteral defect repair treatment or ureteral reconstruction, and is of great significance to the development of ureteral tissue engineering.
Owner:NINGBO FIRST HOSPITAL

Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders

The present invention provides methods, compositions, and kits for treating bladder disorders or conditions, in which botulinum toxin is topically administered to the mucosal inner lining or urothelium of the bladder, of a subject in need thereof, for transmucosal delivery across the urothelium to surrounding bladder wall musculature and / or neuronal tissue. Rather than requiring injection, the toxin instead may be administered by instillation in solution via the urethra. In particular, the botulinum toxin is administered in conjunction with a positively charged or lipophilic carrier comprising a positively charged polymeric backbone or a hydrophobic backbone with covalently attached groups that enhance transmucosal transport across the urothelium and may also stabilize the botulinum toxin in aqueous formulations.
Owner:REVANCE THERAPEUTICS INC

Clostridial Neurotoxin for Use in a Treatment of Bladder Pain Syndrome

The present invention provides a method of treating a patient suffering from bladder pain syndrome, said method comprising administering a solution containing a clostridial neurotoxin into the bladder of the patient; increasing the volume of solution comprising the clostridial neurotoxin present within the bladder, thereby applying a mechanical force against the inner surface of the urothelial layer; and maintaining said volume of solution comprising the clostridial neurotoxin present within the bladder at a volume that does not give rise to patient micturition and for a duration of at least 30 minutes, thereby allowing the clostridial neurotoxin to diffuse across the urothelial layer and into the lamina propria, where the clostridial neurotoxin binds to primary sensory afferent nerve fibres, suppresses secretion of neurotransmitters therefrom, and alleviates bladder pain.
Owner:IPSEN BIOPHARM LTD